Patents by Inventor Akito Natsume
Akito Natsume has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9475886Abstract: The present invention relates to a recombinant antibody composition having higher complement-dependent cytotoxic activity than a human IgG1 antibody and a human IgG3 antibody, wherein a polypeptide comprising a CH2 domain in the Fc region of a human IgG1 antibody is replaced by a polypeptide comprising an amino acid sequence which corresponds to the same position of a human IgG3 antibody indicated by the EU index as in Kabat, et al.; a DNA encoding the antibody molecule or a heavy chain constant region of the antibody molecule contained in the recombinant antibody composition; a transformant obtainable by introducing the recombinant vector into a host cell; a process for producing the recombinant antibody composition using the transformant; and a medicament comprising the recombinant antibody composition as an active ingredient.Type: GrantFiled: September 30, 2014Date of Patent: October 25, 2016Assignee: KYOWA HAKKO KIRIN CO., LTD.Inventors: Kenya Shitara, Rinpei Niwa, Akito Natsume
-
Publication number: 20160108136Abstract: The present invention relates to a recombinant antibody composition having higher complement-dependent cytotoxic activity than a human IgG1 antibody and a human IgG3 antibody, wherein a polypeptide comprising a CH2 domain in the Fc region of a human IgG1 antibody is replaced by a polypeptide comprising an amino acid sequence which corresponds to the same position of a human IgG3 antibody indicated by the EU index as in Kabat, et al.; a DNA encoding the antibody molecule or a heavy chain constant region of the antibody molecule contained in the recombinant antibody composition; a transformant obtainable by introducing the recombinant vector into a host cell; a process for producing the recombinant antibody composition using the transformant; and a medicament comprising the recombinant antibody composition as an active ingredient.Type: ApplicationFiled: September 30, 2014Publication date: April 21, 2016Applicant: KYOWA HAKKO KIRIN CO., LTDInventors: Kenya SHITARA, Rinpei NIWA, Akito NATSUME
-
Patent number: 8883981Abstract: The present invention relates to a recombinant antibody composition having higher complement-dependent cytotoxic activity than a human IgG1 antibody and a human IgG3 antibody, wherein a polypeptide comprising a CH2 domain in the Fc region of a human IgG1 antibody is replaced by a polypeptide comprising an amino acid sequence which corresponds to the same position of a human IgG3 antibody indicated by the EU index as in Kabat, et al.; a DNA encoding the antibody molecule or a heavy chain constant region of the antibody molecule contained in the recombinant antibody composition; a transformant obtainable by introducing the recombinant vector into a host cell; a process for producing the recombinant antibody composition using the transformant; and a medicament comprising the recombinant antibody composition as an active ingredient.Type: GrantFiled: July 2, 2010Date of Patent: November 11, 2014Assignee: Kyowa Hakko Kirin Co., LtdInventors: Kenya Shitara, Rinpei Niwa, Akito Natsume
-
Patent number: 8492526Abstract: Disclosed are a recombinant antibody composition which is a human IgG1 antibody, comprises a CH2 domain in which amino acids at positions 276 and 339 indicated by the EU index as in Kabat, et al. are replaced by other amino acids and has more improved complement-dependent cytotoxic activity than an antibody comprising a CH2 domain before the amino acids are replaced; a DNA encoding the antibody molecule or a heavy chain constant region of the antibody molecule contained in the recombinant antibody composition; a transformant obtainable by introducing the DNA into a host cell; a process for producing the recombinant antibody composition using the transformant; and a medicament comprising the recombinant antibody composition as an active ingredient.Type: GrantFiled: June 22, 2011Date of Patent: July 23, 2013Assignee: Kyowa Hakko Kirin Co., Ltd.Inventors: Kenya Shitara, Rinpei Niwa, Akito Natsume
-
Publication number: 20120022238Abstract: Disclosed are a recombinant antibody composition which is a human IgG1 antibody, comprises a CH2 domain in which amino acids at positions 276 and 339 indicated by the EU index as in Kabat, et al. are replaced by other amino acids and has more improved complement-dependent cytotoxic activity than an antibody comprising a CH2 domain before the amino acids are replaced; a DNA encoding the antibody molecule or a heavy chain constant region of the antibody molecule contained in the recombinant antibody composition; a transformant obtainable by introducing the DNA into a host cell; a process for producing the recombinant antibody composition using the transformant; and a medicament comprising the recombinant antibody composition as an active ingredient.Type: ApplicationFiled: June 22, 2011Publication date: January 26, 2012Applicant: KYOWA HAKKO KIRIN CO., LTDInventors: Kenya SHITARA, Rinpei NIWA, Akito NATSUME
-
Publication number: 20110236374Abstract: The present invention relates to a genetically recombinant antibody composition which specifically binds to ganglioside GM2, which has higher complement-dependent cytotoxic activity than a human IgG1 antibody and a human IgG3 antibody, wherein a polypeptide comprising a CH2 domain in the Fc region of a human IgG1 antibody is replaced by a polypeptide comprising an amino acid sequence which corresponds to the same position of a human IgG3 antibody indicated by the EU index as in Kabat, et al.; a DNA encoding the antibody molecule or a heavy chain constant region of the antibody molecule contained in the recombinant antibody composition; a transformant obtainable by introducing the recombinant vector into a host cell; a process for producing the recombinant antibody composition using the transformant; and a medicament comprising the recombinant antibody composition as an active ingredient.Type: ApplicationFiled: January 24, 2008Publication date: September 29, 2011Applicant: KYOWA HAKKO KIRIN CO., LTD.Inventors: Kenya Shitara, Rinpei Niwa, Akito Natsume
-
Patent number: 7994290Abstract: The present invention relates to a recombinant antibody composition which is a human IgG1 antibody, comprises a CH2 domain in which amino acids at positions 276 and 339 indicated by the EU index as in Kabat, et al. are replaced by other amino acids and has more improved complement-dependent cytotoxic activity than an antibody comprising a CH2 domain before the amino acids are replaced; a DNA encoding the antibody molecule or a heavy chain constant region of the antibody molecule contained in the recombinant antibody composition; a transformant obtainable by introducing the DNA into a host cell; a process for producing the recombinant antibody composition using the transformant; and a medicament comprising the recombinant antibody composition as an active ingredient.Type: GrantFiled: January 24, 2008Date of Patent: August 9, 2011Assignee: Kyowa Hakko Kirin Co., LtdInventors: Kenya Shitara, Rinpei Niwa, Akito Natsume
-
Patent number: 7923538Abstract: The present invention relates to a recombinant antibody composition having higher complement-dependent cytotoxic activity than a human IgG1 antibody and a human IgG3 antibody, wherein a polypeptide comprising a CH2 domain in the Fc region of a human IgG1 antibody is replaced by a polypeptide comprising an amino acid sequence which corresponds to the same position of a human IgG3 antibody indicated by the EU index as in Kabat, et al.; a DNA encoding the antibody molecule or a heavy chain constant region of the antibody molecule contained in the recombinant antibody composition; a transformant obtainable by introducing the recombinant vector into a host cell; a process for producing the recombinant antibody composition using the transformant; and a medicament comprising the recombinant antibody composition as an active ingredient.Type: GrantFiled: July 24, 2006Date of Patent: April 12, 2011Assignee: Kyowa Hakko Kirin Co., LtdInventors: Kenya Shitara, Rinpei Niwa, Akito Natsume
-
Publication number: 20110009600Abstract: The present invention relates to a recombinant antibody composition having higher complement-dependent cytotoxic activity than a human IgG1 antibody and a human IgG3 antibody, wherein a polypeptide comprising a CH2 domain in the Fc region of a human IgG1 antibody is replaced by a polypeptide comprising an amino acid sequence which corresponds to the same position of a human IgG3 antibody indicated by the EU index as in Kabat, et al.; a DNA encoding the antibody molecule or a heavy chain constant region of the antibody molecule contained in the recombinant antibody composition; a transformant obtainable by introducing the recombinant vector into a host cell; a process for producing the recombinant antibody composition using the transformant; and a medicament comprising the recombinant antibody composition as an active ingredient.Type: ApplicationFiled: July 2, 2010Publication date: January 13, 2011Applicant: KYOWA HAKKO KIRIN CO., LTD.Inventors: Kenya SHITARA, Rinpei Niwa, Akito Natsume
-
Publication number: 20090004186Abstract: The present invention relates to a recombinant antibody composition which is a human IgG1 antibody, comprises a CH2 domain in which amino acids at positions 276 and 339 indicated by the EU index as in Kabat, et al. are replaced by other amino acids and has more improved complement-dependent cytotoxic activity than an antibody comprising a CH2 domain before the amino acids are replaced; a DNA encoding the antibody molecule or a heavy chain constant region of the antibody molecule contained in the recombinant antibody composition; a transformant obtainable by introducing the DNA into a host cell; a process for producing the recombinant antibody composition using the transformant; and a medicament comprising the recombinant antibody composition as an active ingredient.Type: ApplicationFiled: January 24, 2008Publication date: January 1, 2009Applicant: KYOWA HAKKO KOGYO CO., LTD.Inventors: Kenya SHITARA, Rinpei NIWA, Akito NATSUME
-
Publication number: 20080241884Abstract: A fusion protein composition of an antibody Fc region which is useful as a medicament in which effector function is improved is desired. The present invention provides a fusion protein composition comprising a fusion protein molecule of an antibody Fc region having complex type N-glycoside-linked sugar chains in the Fc region, wherein the complex type N-glycoside-linked sugar chains have a structure in which fucose is not bound to N-acetylglucosamine in the reducing end in the sugar chains; a transformant producing the fusion protein composition; a process for producing the fusion protein composition; and a medicament comprising the fusion protein composition.Type: ApplicationFiled: October 8, 2004Publication date: October 2, 2008Inventors: Kenya Shitara, Emi Hosaka, Akito Natsume, Masako Wakitani, Kazuhisa Uchida, Mitsuo Satoh, Naoko Ohnuki, Kazuyasu Nakamura
-
Publication number: 20070148165Abstract: The present invention relates to a recombinant antibody composition having higher complement-dependent cytotoxic activity than a human IgG1 antibody and a human IgG3 antibody, wherein a polypeptide comprising a CH2 domain in the Fc region of a human IgG1 antibody is replaced by a polypeptide comprising an amino acid sequence which corresponds to the same position of a human IgG3 antibody indicated by the EU index as in Kabat, et al.; a DNA encoding the antibody molecule or a heavy chain constant region of the antibody molecule contained in the recombinant antibody composition; a transformant obtainable by introducing the recombinant vector into a host cell; a process for producing the recombinant antibody composition using the transformant; and a medicament comprising the recombinant antibody composition as an active ingredient.Type: ApplicationFiled: July 24, 2006Publication date: June 28, 2007Applicant: KYOWA HAKKO KOGYO CO., LTD.Inventors: Kenya Shitara, Rinpei Niwa, Akito Natsume